Understanding the cause of sporadic Alzheimer's disease

Expert Review of Neurotherapeutics

Volumn 14, Issue 6, 2014, Pages 621-630

  Zetterberg, Henrik ^a,b   Mattsson, Niklas ^a,c,d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

aging; Alzheimer's disease; amyloid; apolipoprotein E; neurodegeneration; pathogenesis; tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; SECRETASE; TAU PROTEIN;

ALZHEIMER DISEASE; CLINICAL FEATURE; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; GENETICS; HUMAN; HYPOTHESIS; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NONHUMAN; REVIEW; SENILE PLAQUE; AGING; BRAIN; METABOLISM; PATHOLOGY;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; HUMANS; TAU PROTEINS;

EID: 84901393674     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2014.915740     Document Type: Review

References (130)

1. Förstl H. Contributions of German neuroscience to the concept of Alzheimer disease. In: Whitehouse PJ, Maurer K, Ballenger JF, editors. Concepts of Alzheimer disease: biological, clinical, and cultural perspectives. The Johns Hopkins University Press; Baltimore & London, UK: 2000. p. 72-82
2. Neumann MA, Cohn R. Incidence of Alzheimer's disease in large mental hospital; relation to senile psychosis and psychosis with cerebral arteriosclerosis. AMA Arch Neurol Psychiatry 1953;69(5):615-36
3. Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci 1970;11(3):205-42
4. Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215(4537):1237-9
5. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12(10):383-8
6. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256(5054):184-5
7. Shariati SA, De Strooper B. Redundancy and divergence in the amyloid precursor protein family. FEBS Lett 2013;587(13): 2036-45
8. Walsh DM, Teplow DB. Alzheimer's disease and the amyloid beta-protein. Prog Mol Biol Transl Sci 2012;107:101-24
9. Castellani RJ, Smith MA. Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'. J Pathol 2011;224(2):147-52
10. Castellani RJ, Lee HG, Siedlak SL, et al. Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis 2009;18(2):447-52
11. Hong YT, Veenith T, Dewar D, et al. Amyloid imaging with carbon 11-labeled pittsburgh compound B for traumatic brain injury. JAMA Neurol 2014;71(1):23-31
12. Gustafson DR, Skoog I, Rosengren L, et al. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 2007;78(5):461-4
13. Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013;12(10):957-65
14. Buchhave P, Minthon L, Zetterberg H, et al. Cerebrospinal Fluid Levels of beta-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia. Arch Gen Psychiatry 2012;69(1):98-106
15. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009; 132(Pt 5):1310-23
16. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131(Pt 3):665-80
17. Desikan RS, Sabuncu MR, Schmansky NJ, et al. Selective disruption of the cerebral neocortex in Alzheimer's disease. PLoS One 2010;5(9):e12853
18. Chetelat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010;67(3):317-24
19. Henneman WJ, Vrenken H, Barnes J, et al. Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 2009; 73(12):935-40
20. Tosun D, Schuff N, Shaw LM, et al. Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data. J Alzheimers Dis 2011;26(Suppl 3):77-90
21. Chetelat G, Villemagne VL, Villain N, et al. Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. Neurology 2012; 78(7):477-84
22. Schott JM, Bartlett JW, Fox NC, Barnes J. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42. Ann Neurol 2010;68(6): 825-34
23. Fjell AM, Walhovd KB, Fennema-Notestine C, et al. Brain atrophy in healthy aging is related to CSF levels of Abeta1-42. Cereb Cortex 2010;20(9): 2069-79
24. Chetelat G, Villemagne VL, Pike KE, et al. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 2010;133(11):3349-58
25. Whitwell JL, Tosakulwong N, Weigand SD, et al. Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects? Neuroimage Clin 2013;2: 249-57
26. Mattsson N, Andreasson U, Persson S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 2013;9(3): 251-61
27. Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 2013; 369(4):341-50
28. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370(4):322-33
29. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370(4):311-21
30. Moulder KL, Snider BJ, Mills SL, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther 2013;5(5):48
31. Fjell AM, Walhovd KB. Neuroimaging results impose new views on Alzheimer's disease-the role of amyloid revised. Mol Neurobiol 2012;45(1):153-72
32. Raz N, Lindenberger U, Rodrigue KM, et al. Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. Cereb Cortex 2005;15(11):1676-89
33. Fjell AM, Walhovd KB, Fennema-Notestine C, et al. One-year brain atrophy evident in healthy aging. J Neurosci 2009;29(48):15223-31
34. Fjell AM, McEvoy L, Holland D, et al. Brain changes in older adults at very low risk for Alzheimer's disease. J Neurosci 2013;33(19):8237-42
35. Fjell AM, Walhovd KB, Fennema-Notestine C, et al. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci 2010;30(6):2088-101
36. Knopman DS, Jack CR Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on beta-amyloid in normal elderly. Ann Neurol 2012
37. Wirth M, Villeneuve S, Haase CM, et al. Associations Between Alzheimer Disease Biomarkers, Neurodegeneration, and Cognition in Cognitively Normal Older People. JAMA Neurol 2013
38. Jack CR Jr, Wiste HJ, Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 2013;81(20):1732-40
39. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9(1):119-28
40. Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 2011;121(2):171-81
41. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18(4): 351-7
42. Braak H, Del Tredici K. Reply: the early pathological process in sporadic Alzheimer's disease. Acta Neuropathol 2013;126(4): 615-18
43. Attems J, Jellinger KA. Amyloid and tau: neither chicken nor egg but two partners in crime!. Acta Neuropathol 2013;126(4): 619-21
44. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82(4):239-59
45. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58(12):1791-800
46. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67(3):446-52
47. Mattsson N, Insel P, Nosheny R, et al. Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiol Aging 2014;35(3): 614-22
48. Mungas D, Tractenberg R, Schneider JA, et al. A 2-process model for neuropathology of Alzheimer's disease. Neurobiol Aging 2014;35(2):301-8
49. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013;368(2):117-27
50. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013; 368(2):107-16
51. Pepys MB. Amyloidosis. Annu Rev Med 2006;57:223-41
52. Mattsson N, Insel P, Nosheny R, et al. CSF protein biomarkers predicting longitudinal reduction of CSF beta-amyloid42 in cognitively healthy elders. Transl Psychiatry 2013;3:e293
53. Chavez-Gutierrez L, Bammens L, et al. The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. Embo J 2012; 31(10):2261-74
54. Guerreiro R, Bras J, Hardy J. SnapShot: genetics of Alzheimer's disease. Cell 2013; 155(4):968-8; e961
55. Cruchaga C, Haller G, Chakraverty S, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One 2012;7(2):e31039
56. Kauwe JS, Jacquart S, Chakraverty S, et al. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann Neurol 2007;61(5):446-53
57. Citron M, Teplow DB, Selkoe DJ. Generation of amyloid beta protein from its precursor is sequence specific. Neuron 1995; 14(3):661-70
58. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012;488(7409):96-9
59. Peacock ML, Warren JT Jr, Roses AD, Fink JK. Novel polymorphism in the A4 region of the amyloid precursor protein gene in a patient without Alzheimer's disease. Neurology 1993;43(6):1254-6
60. Andreasson U, Lautner R, Schott JM, et al. CSF biomarkers for Alzheimer's pathology and the effect size of APOE varepsilon4. Mol Psychiatry 2013
61. Bales KR, Liu F, Wu S, et al. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci 2009;29(21):6771-9
62. Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 2011;3(89):89ra57
63. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2009;106(16):6820-5
64. Deane R, Sagare A, Hamm K, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 2008;118(12):4002-13
65. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67(1):122-31
66. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013;9(2):106-18
67. Martinez-Gonzalez NA, Sudlow CL. Effects of apolipoprotein E genotype on outcome after ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2006;77(12):1329-35
68. Zhou W, Xu D, Peng X, et al. Meta-analysis of APOE4 allele and outcome after traumatic brain injury. J Neurotrauma 2008;25(4):279-90
69. Jagust WJ, Landau SM. Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci 2012;32(50):18227-33
70. Knickmeyer RC, Wang J, Zhu H, et al. Common Variants in Psychiatric Risk Genes Predict Brain Structure at Birth. Cereb Cortex 2013
71. Dean DC 3rd, Jerskey BA, Chen K, et al. Brain differences in infants at differential genetic risk for late-onset alzheimer disease: a Cross-sectional Imaging Study. JAMA Neurol 2014;71(1):11-22
72. Hixson JE, Cox LA, Borenstein S. The baboon apolipoprotein E gene: structure, expression, and linkage with the gene for apolipoprotein C-1. Genomics 1988;2(4): 315-23
73. Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE4 a 'thrifty' allele Ann Hum Genet 1999;63(Pt 4):301-10
74. Scacchi R, Corbo RM, Rickards O, et al. Apolipoprotein B and E genetic polymorphisms in the Cayapa Indians of Ecuador. Hum Biol 1997;69(3):375-82
75. Fujioka H, Phelix CF, Friedland RP, et al. Apolipoprotein E4 prevents growth of malaria at the intraerythrocyte stage: implications for differences in racial susceptibility to Alzheimer's disease. J Health Care Poor Underserved 2013; 24(4 Suppl):70-8
76. Zetterberg H, Palmer M, Ricksten A, et al. Influence of the apolipoprotein E epsilon4 allele on human embryonic development. Neurosci Lett 2002;324(3): 189-92
77. Becher JC, Bell JE, McIntosh N, Keeling JW. Distribution of apolipoprotein E alleles in a Scottish healthy newborn population. Biol Neonate 2005;88(3):164-7
78. Becher JC, Keeling JW, McIntosh N, et al. The distribution of apolipoprotein E alleles in Scottish perinatal deaths. J Med Genet 2006;43(5):414-18
79. Han SD, Bondi MW. Revision of the apolipoprotein E compensatory mechanism recruitment hypothesis. Alzheimers Dement 2008;4(4):251-4
80. Ogunniyi A, Baiyewu O, Gureje O, et al. Epidemiology of dementia in Nigeria: results from the Indianapolis-Ibadan study. Eur J Neurol 2000;7(5):485-90
81. Jones L, Holmans PA, Hamshere ML, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One 2010;5(11):e13950
82. Armstrong A, Mattsson N, Appelqvist H, et al. Lysosomal Network Proteins as Potential Novel CSF Biomarkers for Alzheimer's Disease. Neuromolecular Med 2013
83. Daborg J, Andreasson U, Pekna M, et al. Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease. J Neural Transm 2012;119(7): 789-97
84. Mattsson N, Tabatabaei S, Johansson P, et al. Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med 2011;13(2): 151-9
85. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368(9533): 387-403
86. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985; 43(2 Pt 1):405-13
87. Rodier F, Campisi J, Bhaumik D. Two faces of p53: aging and tumor suppression. Nucleic Acids Res 2007;35(22):7475-84
88. Koike MA, Green KN, Blurton-Jones M, Laferla FM. Oligemic hypoperfusion differentially affects tau and amyloid-{beta}. Am J Pathol 2010;177(1):300-10
89. Guglielmotto M, Aragno M, Autelli R, et al. The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J Neurochem 2009;108(4): 1045-56
90. Wang X, Xing A, Xu C, et al. Cerebrovascular hypoperfusion induces spatial memory impairment, synaptic changes, and amyloid-beta oligomerization in rats. J Alzheimers Dis 2010;21(3): 813-22
91. Qi JP, Wu H, Yang Y, et al. Cerebral ischemia and Alzheimer's disease: the expression of amyloid-beta and apolipoprotein E in human hippocampus. J Alzheimers Dis 2007;12(4):335-41
92. Zetterberg H, Mortberg E, Song L, et al. Hypoxia Due to Cardiac Arrest Induces a Time-Dependent Increase in Serum Amyloid beta Levels in Humans. PLoS One 2011;6(12):e28263
93. Wisniewski HM, Maslinska D. Beta-protein immunoreactivity in the human brain after cardiac arrest. Folia Neuropathol 1996; 34(2):65-71
94. Hooshmand B, Solomon A, Kareholt I, et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease. A longitudinal study. Neurology 2010;75(16): 1408-14
95. Li J, Wang YJ, Zhang M, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 2011;76(17):1485-91
96. Solomon A, Kivipelto M, Wolozin B, et al. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord 2009;28(1):75-80
97. Guo X, Pantoni L, Simoni M, et al. Blood pressure components and changes in relation to white matter lesions: a 32-year prospective population study. Hypertension 2009;54(1):57-62
98. Reitz C, Mayeux R. Alzheimer disease: Epidemiology, Diagnostic Criteria, Risk Factors and Biomarkers. Biochem Pharmacol 2014
99. Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet 2013; 382(9902):1405-12
100. Qiu C, von Strauss E, Backman L, et al. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology 2013;80(20):1888-94
101. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013;80(19): 1778-83
102. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69(24):2197-204
103. James BD, Bennett DA, Boyle PA, et al. Dementia from Alzheimer disease and mixed pathologies in the oldest old. Jama 2012;307(17):1798-800
104. Davidson YS, Raby S, Foulds PG, et al. TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol 2011;122(6): 703-13
105. Toledo JB, Cairns NJ, Da X, et al. Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun 2013;1(1):65
106. Jellinger KA, Attems J. Prevalence and pathology of dementia with Lewy bodies in the oldest old: a comparison with other dementing disorders. Dement Geriatr Cogn Disord 2011;31(4):309-16
107. Hansen LA, Masliah E, Galasko D, Terry RD. Plaque-only Alzheimer disease is usually the lewy body variant, and vice versa. J Neuropathol Exp Neurol 1993; 52(6):648-54
108. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009; 66(2):200-8
109. Olichney JM, Galasko D, Salmon DP, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology 1998;51(2):351-7
110. Iadecola C. The pathobiology of vascular dementia. Neuron 2013;80(4):844-66
111. Wallin A, Ohrfelt A, Bjerke M. Characteristic clinical presentation and CSF biomarker pattern in cerebral small vessel disease. J Neurol Sci 2012;322(1-2):192-6
112. Warren JD, Fletcher PD, Golden HL. The paradox of syndromic diversity in Alzheimer disease. Nat Rev Neurol 2012;8(8):451-64
113. Crutch SJ, Lehmann M, Schott JM, et al. Posterior cortical atrophy. Lancet Neurol 2012;11(2):170-8
114. Grossman M. Primary progressive aphasia: clinicopathological correlations. Nat Rev Neurol 2010;6(2):88-97
115. Teichmann M, Kas A, Boutet C, et al. Deciphering logopenic primary progressive aphasia: a clinical, imaging and biomarker investigation. Brain 2013;136(Pt 11): 3474-88
116. Lee SE, Rabinovici GD, Mayo MC, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol 2011;70(2):327-40
117. Ridgway GR, Lehmann M, Barnes J, et al. Early-onset Alzheimer disease clinical variants. multivariate analyses of cortical thickness. Neurology 2012;79(1):80-4
118. Migliaccio R, Agosta F, Rascovsky K, et al. Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology 2009;73(19):1571-8
119. Lehmann M, Madison CM, Ghosh PM, et al. Intrinsic connectivity networks in healthy subjects explain clinical variability in Alzheimer's disease. Proc Natl Acad Sci USA 2013;110(28):11606-11
120. Lehmann M, Ghosh PM, Madison C, et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain 2013; 136(Pt 3):844-58
121. Rosenbloom MH, Alkalay A, Agarwal N, et al. Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology 2011;76(21): 1789-96
122. Rogalski E, Johnson N, Weintraub S, Mesulam M. Increased frequency of learning disability in patients with primary progressive aphasia and their first-degree relatives. Arch Neurol 2008;65(2):244-8
123. Mesulam MM. Primary progressive aphasia and the language network: the 2013 H. Houston Merritt Lecture. Neurology 2013; 81(5):456-62
124. Tang-Wai DF, Graff-Radford NR, Boeve BF, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004;63(7): 1168-74
125. Gefen T, Gasho K, Rademaker A, et al. Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia. Brain 2012;135(Pt 5): 1554-65
126. Johnson JK, Head E, Kim R, et al. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol 1999;56(10):1233-9
127. Filippini N, Rao A, Wetten S, et al. Anatomically-distinct genetic associations of APOE epsilon4 allele load with regional cortical atrophy in Alzheimer's disease. Neuroimage 2009;44(3):724-8
128. Mattsson N, Portelius E, Rolstad S. Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. J Alzheimers Dis 2012;30(4): 767-78
129. Moghekar A, Li S, Lu Y, et al. CSF biomarker changes precede symptom onset of mild cognitive impairment. Neurology 2013
130. Le Couteur DG, Doust J, Creasey H, Brayne C. Political drive to screen for predementia: not evidence based and ignores the harms of diagnosis. BMJ 2013;347: f5125